Cargando…

Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms

The presence of an isocitrate dehydrogenase 1 (IDH1) mutation is associated with a less aggressive phenotype, increased sensitivity to radiation, and increased overall survival in patients with diffuse glioma. Based on in vitro experimentations in malignant glioma cell lines, the consequences on cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kessler, Jacqueline, Hohmann, Tim, Güttler, Antje, Petrenko, Marina, Ostheimer, Christian, Hohmann, Urszula, Bache, Matthias, Dehghani, Faramarz, Vordermark, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627228/ https://www.ncbi.nlm.nih.gov/pubmed/31242696 http://dx.doi.org/10.3390/cancers11060889

Ejemplares similares

Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer
por: Ostheimer, Christian, et al.
Publicado: (2014)

Evaluation of machine learning models for automatic detection of DNA double strand breaks after irradiation using a γH2AX foci assay
por: Hohmann, Tim, et al.
Publicado: (2020)

MACC1-induced migration in tumors: Current state and perspective
por: Hohmann, Tim, et al.
Publicado: (2023)

SESN2 Knockdown Increases Betulinic Acid-Induced Radiosensitivity of Hypoxic Breast Cancer Cells
por: Güttler, Antje, et al.
Publicado: (2022)

The Impact of Non-Lethal Single-Dose Radiation on Tumor Invasion and Cytoskeletal Properties
por: Hohmann, Tim, et al.
Publicado: (2017)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Betulinyl Sulfamates as Anticancer Agents and Radiosensitizers in Human Breast Cancer Cells
por: Bache, Matthias, et al.
Publicado: (2015)

Assessment of Neuronal Damage in Brain Slice Cultures Using Machine Learning Based on Spatial Features
por: Hohmann, Urszula, et al.
Publicado: (2021)

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP(+)-dependent isocitrate dehydrogenase (IDH)
por: Yang, Jinsung, et al.
Publicado: (2017)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

MACC1-Induced Collective Migration Is Promoted by Proliferation Rather Than Single Cell Biomechanics
por: Hohmann, Tim, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells
por: Shait Mohammed, Mohammed Razeeth, et al.
Publicado: (2022)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1
por: Cordner, Ryan, et al.
Publicado: (2023)

Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells
por: Güttler, Antje, et al.
Publicado: (2021)

MACC1 driven alterations in cellular biomechanics facilitate cell motility in glioblastoma
por: Hohmann, Tim, et al.
Publicado: (2020)

Correlation between Circulating miR-16, miR-29a, miR-144 and miR-150, and the Radiotherapy Response and Survival of Non-Small-Cell Lung Cancer Patients
por: Bache, Matthias, et al.
Publicado: (2023)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning
por: Liu, Sidong, et al.
Publicado: (2020)

Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant
por: Herold, Ryan A., et al.
Publicado: (2021)

Opposite Effects of Neuroprotective Cannabinoids, Palmitoylethanolamide, and 2-Arachidonoylglycerol on Function and Morphology of Microglia
por: Hohmann, Urszula, et al.
Publicado: (2019)

Interaction of Glia Cells with Glioblastoma and Melanoma Cells under the Influence of Phytocannabinoids
por: Hohmann, Urszula, et al.
Publicado: (2022)

Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City
por: Olarte, Irma, et al.
Publicado: (2019)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas
por: Amary, M. Fernanda, et al.
Publicado: (2014)

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
por: Chotirat, Sadudee, et al.
Publicado: (2012)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
por: van Lith, Sanne A. M., et al.
Publicado: (2016)

Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation
por: KAWAKAMI, Shota, et al.
Publicado: (2017)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

The Cytoskeleton—A Complex Interacting Meshwork
por: Hohmann, Tim, et al.
Publicado: (2019)

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism
por: Mir Seyed Nazari, P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tdcvak0p9rs627328p9t8udee4